CL2024001225A1 - Composiciones que actúan sobre bcma y métodos de uso de estas - Google Patents
Composiciones que actúan sobre bcma y métodos de uso de estasInfo
- Publication number
- CL2024001225A1 CL2024001225A1 CL2024001225A CL2024001225A CL2024001225A1 CL 2024001225 A1 CL2024001225 A1 CL 2024001225A1 CL 2024001225 A CL2024001225 A CL 2024001225A CL 2024001225 A CL2024001225 A CL 2024001225A CL 2024001225 A1 CL2024001225 A1 CL 2024001225A1
- Authority
- CL
- Chile
- Prior art keywords
- bcma
- binding agents
- car
- present
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/21—Transmembrane domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/25—Suicide switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257822P | 2021-10-20 | 2021-10-20 | |
| US202163257846P | 2021-10-20 | 2021-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001225A1 true CL2024001225A1 (es) | 2024-10-18 |
Family
ID=84361139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001225A CL2024001225A1 (es) | 2021-10-20 | 2024-04-18 | Composiciones que actúan sobre bcma y métodos de uso de estas |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12290531B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4419561A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024539506A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240099161A (cg-RX-API-DMAC7.html) |
| AR (1) | AR127408A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022372894A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236038A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024001225A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024004796A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311837A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004365A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20242001A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202330612A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023068382A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3253069A1 (en) * | 2022-05-31 | 2023-12-07 | Oncopeptides Innovation 1 Ab | NEW POLYPEPTIDES |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| JP2026512487A (ja) * | 2023-04-18 | 2026-04-16 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Bcmaキメラ抗原受容体及びその使用 |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2026006767A1 (en) | 2024-06-28 | 2026-01-02 | Dispatch Biotherapeutics, Inc. | Tethered il-9/il-9r and related engineered cells and methods |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3681787D1 (de) | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| HK1008049A1 (en) | 1987-09-11 | 1999-04-30 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and use therefor |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| ATE110108T1 (de) | 1987-12-11 | 1994-09-15 | Whitehead Biomedical Inst | Genetische modifizierung von endothelialen zellen. |
| DE68927996T2 (de) | 1988-02-05 | 1997-12-04 | Hughes Howard Med Inst | Modifizierte hepatozyten und deren anwendung |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE69123981T3 (de) | 1990-10-31 | 2006-06-14 | Cell Genesys Inc | Nützliche retrovirale vektoren für die gentherapie |
| JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| JPH08506247A (ja) | 1993-07-09 | 1996-07-09 | アムジェン ボールダー インコーポレイテッド | 組換えctla4ポリペプチドおよびその製造方法 |
| US5308341A (en) | 1993-09-28 | 1994-05-03 | Becton, Dickinson And Company | Method of testing the dose accuracy of a medication delivery device |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
| US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| NZ513356A (en) | 1999-02-05 | 2004-01-30 | Univ Leiden | Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate |
| US6192891B1 (en) | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| WO2001009300A2 (en) | 1999-08-02 | 2001-02-08 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| US6277099B1 (en) | 1999-08-06 | 2001-08-21 | Becton, Dickinson And Company | Medication delivery pen |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| ATE547080T1 (de) | 2000-08-30 | 2012-03-15 | Univ Johns Hopkins | Vorrichtungen zur intraokularen arzneimittelabgabe |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| JP4383168B2 (ja) | 2001-09-12 | 2009-12-16 | ベクトン・ディキンソン・アンド・カンパニー | マイクロ針投与デバイスおよび薬物投与デバイス |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US20040102469A1 (en) | 2002-09-13 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for reducing the mortality rate |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| EP1565482B1 (en) | 2002-10-23 | 2014-04-30 | Ludwig Institute for Cancer Research Ltd. | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
| FR2849436B1 (fr) | 2002-12-27 | 2007-01-05 | Patrick Frayssinet | Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro |
| WO2004073551A2 (en) | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| CA2693771A1 (en) | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3053932B1 (en) | 2010-02-19 | 2020-07-22 | Xencor, Inc. | Novel ctla4-ig immunoadhesins |
| NZ602220A (en) | 2010-03-11 | 2014-10-31 | Rinat Neuroscience Corp | Antibodies with ph dependent antigen binding |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| CN105682683A (zh) | 2013-08-02 | 2016-06-15 | 阿杜罗生物科技控股有限公司 | 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| MA45498A (fr) * | 2016-06-16 | 2019-04-24 | Memorial Sloan Kettering Cancer Center | Cellules treg génétiquement modifiées |
| SG11201900885VA (en) * | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| JP7240335B2 (ja) * | 2017-06-20 | 2023-03-15 | テネオワン, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
| WO2019099707A1 (en) * | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
| CN113272320A (zh) | 2018-11-19 | 2021-08-17 | 得克萨斯大学体系董事会 | 自杀基因 |
| WO2020227446A1 (en) | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| JP2022548902A (ja) | 2019-09-18 | 2022-11-22 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Bcma陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 |
| CN113248611B (zh) * | 2020-02-13 | 2026-02-06 | 上海泰槿生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
-
2022
- 2022-10-19 AU AU2022372894A patent/AU2022372894A1/en active Pending
- 2022-10-19 WO PCT/JP2022/040573 patent/WO2023068382A2/en not_active Ceased
- 2022-10-19 IL IL311837A patent/IL311837A/en unknown
- 2022-10-19 EP EP22809538.6A patent/EP4419561A2/en active Pending
- 2022-10-19 PE PE2024000888A patent/PE20242001A1/es unknown
- 2022-10-19 AR ARP220102846A patent/AR127408A1/es unknown
- 2022-10-19 JP JP2024548066A patent/JP2024539506A/ja active Pending
- 2022-10-19 MX MX2024004365A patent/MX2024004365A/es unknown
- 2022-10-19 TW TW111139693A patent/TW202330612A/zh unknown
- 2022-10-19 CA CA3236038A patent/CA3236038A1/en active Pending
- 2022-10-19 KR KR1020247011576A patent/KR20240099161A/ko active Pending
-
2024
- 2024-04-17 CO CONC2024/0004796A patent/CO2024004796A2/es unknown
- 2024-04-18 CL CL2024001225A patent/CL2024001225A1/es unknown
- 2024-04-19 US US18/640,982 patent/US12290531B2/en active Active
-
2025
- 2025-03-26 US US19/090,598 patent/US20250339466A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311837A (en) | 2024-05-01 |
| EP4419561A2 (en) | 2024-08-28 |
| CO2024004796A2 (es) | 2024-05-20 |
| US20240350544A1 (en) | 2024-10-24 |
| CA3236038A1 (en) | 2023-04-27 |
| JP2024539506A (ja) | 2024-10-28 |
| WO2023068382A2 (en) | 2023-04-27 |
| MX2024004365A (es) | 2024-04-25 |
| AR127408A1 (es) | 2024-01-17 |
| US12290531B2 (en) | 2025-05-06 |
| TW202330612A (zh) | 2023-08-01 |
| US20250339466A1 (en) | 2025-11-06 |
| AU2022372894A1 (en) | 2024-04-18 |
| WO2023068382A3 (en) | 2023-07-06 |
| PE20242001A1 (es) | 2024-09-27 |
| KR20240099161A (ko) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024004796A2 (es) | Composiciones que actúan sobre bcma y métodos de uso de estas | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| CL2019001324A1 (es) | Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos. | |
| WO2017172981A3 (en) | Chimeric antigen receptors targeting cancer | |
| MX2021011196A (es) | Receptores de antigenos quimericos anti-antigeno de maduracion de celulas b (anti-bcma). | |
| CR9819A (es) | Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina | |
| PE20200485A1 (es) | Proteinas de union a antigenos trem2 y usos de estas | |
| MX2023015101A (es) | Polipeptidos que se dirigen a canceres cd70-positivos. | |
| DOP2013000128A (es) | Uso de células t modificadas con un receptor de antígeno quimérico para tratar el cáncer | |
| WO2019215510A8 (en) | Compositions and methods related to anti-cd19 antibody drug conjugates | |
| MX2021003636A (es) | Receptor antigenico quimerico. | |
| MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
| EA202190926A1 (ru) | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей | |
| MX2024001943A (es) | Receptores de antigeno quimerico (car) para las malignancias de celulas b. | |
| CO2025002163A2 (es) | Receptores quiméricos de antígeno específicos para gprc5d y bcma | |
| CR9995A (es) | Anticuerpos monoclonales bifuncionales contra la placa beta amiloide | |
| CY1115382T1 (el) | Συνθεσεις και μεθοδοι για αναστολη toy pdgfrb και toy vegf-a | |
| AR048098A1 (es) | Conjugados de caliqueamicina | |
| DOP2013000045A (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| WO2009091826A3 (en) | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| BR112021012667A2 (pt) | Proteínas de ligação anti-pd-1 e métodos de uso destas | |
| PE20221273A1 (es) | Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos | |
| EA202192413A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ | |
| WO2021048564A3 (en) | Antigen-binding domain |